Current and future anti-fibrotic therapies for chronic liver disease.

Abstract

Chronic injury results in a wound healing response that eventually leads to fibrosis. The response is generalized, with features common among multiple organ systems. In the liver, various different types of injury lead to fibrogenesis, implying a common pathogenesis. Although several specific therapies for patients who have different liver diseases have been successfully developed, including antiviral therapies for those who have hepatitis B and hepatitis C virus infection, specific and effective antifibrotic therapy remains elusive. Over the past 2 decades, great advances in the understanding of fibrosis have been made and multiple mechanisms underlying hepatic fibrogenesis uncovered. Elucidation of these mechanisms has been of fundamental importance in highlighting novel potential therapies. Preclinical studies have indicated several putative therapies that might abrogate fibrogenesis. This article emphasizes mechanisms underlying fibrogenesis and reviews available and future therapeutics.

DOI: 10.1016/j.cld.2008.07.011
02040200920102011201220132014201520162017
Citations per Year

154 Citations

Semantic Scholar estimates that this publication has 154 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Rockey2008CurrentAF, title={Current and future anti-fibrotic therapies for chronic liver disease.}, author={Don C. Rockey}, journal={Clinics in liver disease}, year={2008}, volume={12 4}, pages={939-62, xi} }